Oncology Data Advisor i3 Health

In celebration of Head and Neck Cancer Awareness Month this April, Oncology Data Advisor Fellows Forum and Editorial Board Members Samuel Kareff, MD, MPH; Matthew Hadfield, DO; and Nagashree Seetharamu, MD, sat down to discuss the epidemiology of head and neck squamous cell carcinomas (HNSCC), the diagnostic and treatment process of HNSCC, including:
–Epidemiologic trends
–Geographic distribution
–Approved screening methods
–Novel treatment combinations
–Side effects and adverse events
–Survivorship
–And more!

This April, Oncology Data Advisor is raising awareness for Esophageal Cancer Awareness Month. In this interview, Oncology Data Advisor Editorial Board and Fellows Forum members Dr. Joseph Kalis, Dr. Matthew Hadfield, and Dr. Samuel Kareff discuss rising trends, treatment advances, and emerging management strategies for esophageal cancer, including the following:
• The rising rate of adenocarcinoma in the context of pre-existing esophageal dysplasia and Barrett esophagus
• Risk factors such as tobacco and alcohol
• The roles of healthy eating and smoking cessation in esophageal cancer prevention
• How the rise of immunotherapies such as pembrolizumab, nivolumab, and trastuzumab have changed practice
• This month’s approval of fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2 (HER2)–positive solid tumors
• Lifestyle interventions such as following the Mediterranean diet and United States Preventive Services Task Force (USPSTF) exercise guidelines that can make maximize tolerability of therapy

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute.

At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including:
• The study design, which includes triple-class–refractory patients
• The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience
• The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients
• Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections
• The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation
• And more!

In this interview, Jason Mouabbi, MD, an Oncology Data Advisor Editorial Board Member and Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, sat down with Valerie Brutus, MD, FACS, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, and Elizabeth Stirling Craig, MD, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, to discuss improving breast cancer surgical outcomes with lymphovenous bypass surgery.

Dr. Mouabbi engages Dr. Brutus and Dr. Craig in a thought-provoking discussion about lymphovenous bypass surgery: what it is, who qualifies for this procedure, its viability, what to expect from this procedure and its treatment process, and more about breast cancer surgical outcomes.

Adolescent and Young Adult (AYA) Cancer Awareness Week, April 1 to 5, 2024, is a time to shine a spotlight on adolescent and young adult cancer patients and survivors. To commemorate the week, Lauren Ghazal, Megan-Claire Chase, and Allison Rosen, all members of the Oncology Data Advisor Editorial Board, sat down for a conversation to highlight the issues that AYA cancer patients face, including fertility preservation and financial toxicity; the need to ensure that race, ethnicity, and sexual orientation are not overlooked when building welcoming support spaces for all patients; and the value of turning to the AYA community for support while also serving as your own best advocate.

Dr. Christopher Lieu, Associate Director of Clinical Research at the University of Colorado Cancer Center and Vice Chair of the National Comprehensive Cancer Network (NCCN), is currently serving as chair of i3 Health's online activity, live webinar, and meeting series, Hitting the Target in HER2-Positive Metastatic Colorectal Cancer. With numerous research advances occurring in this field during the past year, Dr. Lieu sat down with us again to share updates in targeted therapies for HER2-positive metastatic colorectal cancer and the evolving landscape of biomarkers under investigation for this disease.

Click the links below for Hitting the Target in HER2-Positive Metastatic Colorectal Cancer, an accredited CME/NCPD activity provided by i3 Health!

Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer

Live Webinar Registration: https://www.i3health.com/course-information/Colorectal-Cancer-Webinar

Live or Virtual Meeting Series: https://www.i3health.com/live/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer-1